Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.

Condition:   Atrial Fibrillation (AF) Interventions:   Drug: BAY2433334;   Drug: Apixaban;   Other: BAY2433334 matching placebo;   Other: Apixaban matching placebo Sponsor:   Bayer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials